Back to Search Start Over

Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.

Authors :
Stefanini, Giulio G.
Chiarito, Mauro
Ferrante, Giuseppe
Cannata, Francesco
Azzolini, Elena
Viggiani, Giacomo
De Marco, Andrea
Briani, Martina
Bocciolone, Monica
Bragato, Renato
Corrada, Elena
Gasparini, Gabriele L.
Marconi, Manuel
Monti, Lorenzo
Pagnotta, Paolo A.
Panico, Cristina
Pini, Daniela
Regazzoli, Damiano
My, Ilaria
Kallikourdis, Marinos
Source :
Heart; Oct2020, Vol. 106 Issue 19, p1512-1518, 7p
Publication Year :
2020

Abstract

<bold>Objective: </bold>Risk stratification is crucial to optimise treatment strategies in patients with COVID-19. We aimed to evaluate the impact on mortality of an early assessment of cardiac biomarkers in patients with COVID-19.<bold>Methods: </bold>Humanitas Clinical and Research Hospital (Rozzano-Milan, Lombardy, Italy) is a tertiary centre that has been converted to the management of COVID-19. Patients with confirmed COVID-19 were entered in a dedicated database for cohort observational analyses. Outcomes were stratified according to elevated levels (ie, above the upper level of normal) of high-sensitivity cardiac troponin I (hs-TnI), B-type natriuretic peptide (BNP) or both measured within 24 hours after hospital admission. The primary outcome was all-cause mortality.<bold>Results: </bold>A total of 397 consecutive patients with COVID-19 were included up to 1 April 2020. At the time of hospital admission, 208 patients (52.4%) had normal values for cardiac biomarkers, 90 (22.7%) had elevated both hs-TnI and BNP, 59 (14.9%) had elevated only BNP and 40 (10.1%) had elevated only hs-TnI. The rate of mortality was higher in patients with elevated hs-TnI (22.5%, OR 4.35, 95% CI 1.72 to 11.04), BNP (33.9%, OR 7.37, 95% CI 3.53 to 16.75) or both (55.6%, OR 18.75, 95% CI 9.32 to 37.71) as compared with those without elevated cardiac biomarkers (6.25%). A multivariate analysis identified concomitant elevation of both hs-TnI and BNP as a strong independent predictor of all-cause mortality (OR 3.24, 95% CI 1.06 to 9.93).<bold>Conclusions: </bold>An early detection of elevated hs-TnI and BNP predicts mortality in patients with COVID-19. Cardiac biomarkers should be systematically assessed in patients with COVID-19 at the time of hospital admission in order to optimise risk stratification. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13556037
Volume :
106
Issue :
19
Database :
Complementary Index
Journal :
Heart
Publication Type :
Academic Journal
Accession number :
145969480
Full Text :
https://doi.org/10.1136/heartjnl-2020-317322